- Trials with a EudraCT protocol (5,937)
- Paediatric studies in scope of Art45 of the Paediatric Regulation (0)
5,937 result(s) found for: Chronic Disease.
Displaying page 141 of 297.
| EudraCT Number: 2007-007977-21 | Sponsor Protocol Number: GS07/8360 | Start Date*: 2008-11-12 |
| Sponsor Name:Leeds Teaching Hospitals Trust | ||
| Full Title: ASSESSMENT OF THE ROLE OF THE PROBIOTIC VSL3® IN THE TREATMENT OF POUCHITIS AFTER ILEAL POUCH-ANAL ANASTOMOSIS | ||
| Medical condition: This study aims to assess the bacterial flora in patients with healthy pouches and patients with have pouchitis. We aim to study the clinical and microbiological effectiveness of antibiotic and pro... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: GB (GB - no longer in EU/EEA) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-002160-28 | Sponsor Protocol Number: hepatology_MT_2005-05 | Start Date*: 2005-09-23 |
| Sponsor Name:Medical University Graz,Department of Internal Medicine, Division of Gastroenterology and Hepatology | ||
| Full Title: Safety and efficacy of long-term treatment with atorvastatin in patients with primary biliary cirrhosis | ||
| Medical condition: Reduction of cardiovascular risk may become key for the management of PBC. Therefore information on safety and efficacy (lipid-lowering effects) of statins in chronic cholestatic disorders is essen... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-002984-14 | Sponsor Protocol Number: AC-064A201 | Start Date*: 2015-06-05 |
| Sponsor Name:ACTELION Pharmaceuticals Ltd | ||
| Full Title: A multicenter, randomized, double-blind, placebo-controlled, dose-response study to investigate the biological activity, safety, tolerability, and pharmacokinetics of ACT-334441 in subjects with sy... | ||
| Medical condition: Systemic lupus erythematosus | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: BG (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2009-010381-30 | Sponsor Protocol Number: 2.4 | Start Date*: 2009-03-19 | |||||||||||
| Sponsor Name:Isala klinieken | |||||||||||||
| Full Title: Aerosolised salbutamol in two doses as a treatment for preterm infants with developing bronchopulmonary dysplasia. | |||||||||||||
| Medical condition: Preterm infants developing bronchopulmonary dysplasia | |||||||||||||
|
|||||||||||||
| Population Age: Preterm newborn infants, Newborns, Under 18 | Gender: Male, Female | ||||||||||||
| Trial protocol: NL (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2006-004435-30 | Sponsor Protocol Number: SC06-02 | Start Date*: 2006-10-31 | |||||||||||
| Sponsor Name:FONDAZIONE SANTA LUCIA | |||||||||||||
| Full Title: Protocol of study for the evaluation of the efficacy of rivastigmine on cognitive and behavioural disorders, following traumatic brain injury TBI in chronic patients. | |||||||||||||
| Medical condition: Patients with cognitive and behavioural disorders following severe TBI and other severe acquired brain injury Glasgow Coma Scale GCS lower or equal 8 | |||||||||||||
|
|||||||||||||
| Population Age: Adults | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Ongoing) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2005-003587-34 | Sponsor Protocol Number: IPR/01 | Start Date*: 2007-04-12 |
| Sponsor Name:MolMed | ||
| Full Title: A phase I-II study: infusion of donor lymphocytes transduced with the suicide gene HSV TK, after transplantation of allogeneic T-depleted stem cells from a haploidentical donor in patients with hae... | ||
| Medical condition: Hematological malignancies at high risk of relapse based on disease progression or presence of negative prognostic factor, who have received a HCTfrom donor HLA mismatched (haploidentical) for 2 o... | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GR (Ongoing) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2005-005664-88 | Sponsor Protocol Number: HB996 | Start Date*: 2006-12-08 |
| Sponsor Name:University of Oxford | ||
| Full Title: Prospective Study of Mycobacterium Tuberculosis Specific Cellular immune Responses in Iatrogenically Immunosuppressed Patients: those undergoing TNF-alpha blockade or Awaiting Renal Trasnplants: A ... | ||
| Medical condition: Renal failure and iatrogenic immunosuppression associated with solid organ transplantation or TNF alpha blockade in rheumatoid arthritis ICD 10 codes included: N18 Z94.0 M05 M06 M07 M45 | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: GB (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2014-001552-29 | Sponsor Protocol Number: 1271/2014 | Start Date*: 2014-06-20 |
| Sponsor Name:Medizinische Universität Wien, Abteilung für Anästhesie und allgemeine Intensivmedizin | ||
| Full Title: Determination of the minimal alveolar concentration of Sevoflurane in patient with end stage liver disease | ||
| Medical condition: Orthotopic liver transplantation (OLT) is the only therapy for patients with liver failure. These patients have reduced anesthetic requirements compared with healthy patients. Sevoflurane has prove... | ||
| Disease: | ||
| Population Age: Adults | Gender: Male, Female | |
| Trial protocol: AT (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2020-001603-16 | Sponsor Protocol Number: COLCHI-COVID | Start Date*: 2020-05-06 | |||||||||||
| Sponsor Name:IDIVAL | |||||||||||||
| Full Title: A RANDOMIZATION, MULTICENTRIC, OPEN-LABEL, CONTROLLED, CLINICAL TRIAL TO INVESTIGATE THE EFFECTIVENESS OF EARLY CHOLCHICINE ADMINISTRATION IN PATIENTS OVER 70 YEARS OF AGE WITH HIGH RISK OF DEVELOP... | |||||||||||||
| Medical condition: Adult patients over 70 years of age diagnosed by COVID-19 with outpatient follow-up | |||||||||||||
|
|||||||||||||
| Population Age: Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: ES (Completed) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2021-005013-14 | Sponsor Protocol Number: MKIA-088-002 | Start Date*: 2022-01-11 | |||||||||||
| Sponsor Name:NERVIANO MEDICAL SCIENCES SRL | |||||||||||||
| Full Title: A Phase I/II Combination Study of NMS-03592088 And Azacitidine for the Treatment of Patients With FLT3-Mutated AML with Relapsed /Refractory Disease or Who Are Unfit For Intensive Chemotherapy, or ... | |||||||||||||
| Medical condition: Acute Myeloid Leukemia (AML) and Chronic Myelomonocytic Leukemia (CMML) | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: IT (Prematurely Ended) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-003837-13 | Sponsor Protocol Number: ROPPET-NAF | Start Date*: 2020-04-20 |
| Sponsor Name:Centro Hospitalar e Universitário de Coimbra, E.P.E. | ||
| Full Title: Rosuvastatin effect on atherosclerotic plaque metabolism ¿ a subclinical atherosclerosis imaging study with 18F-NaF PET-CT | ||
| Medical condition: Atherosclerosis, namely in the aorta, carotid and coronary arteries | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: PT (Completed) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2011-000831-10 | Sponsor Protocol Number: E5501-G000-305 | Start Date*: 2012-07-16 | ||||||||||||||||||||||||||
| Sponsor Name:Eisai Limited | ||||||||||||||||||||||||||||
| Full Title: A Phase 3, Multicenter, Randomized, Double-blind, Active-controlled, Parallel-group Trial with an Open-label Extension Phase to Evaluate the Efficacy and Safety of Oral E5501 versus Eltrombopag, i... | ||||||||||||||||||||||||||||
| Medical condition: Chronic Immune Thrombocytopenia (Idiopathic Thrombocytopenic Purpura) | ||||||||||||||||||||||||||||
|
||||||||||||||||||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | |||||||||||||||||||||||||||
| Trial protocol: BE (Prematurely Ended) DE (Prematurely Ended) AT (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) ES (Prematurely Ended) | ||||||||||||||||||||||||||||
| Trial results: View results | ||||||||||||||||||||||||||||
| EudraCT Number: 2006-001859-35 | Sponsor Protocol Number: cro632 | Start Date*: 2007-04-13 | |||||||||||
| Sponsor Name:Imperial College London | |||||||||||||
| Full Title: Abatacept in ANCA associated vasculitis: ABAVAS | |||||||||||||
| Medical condition: Anti-neutrophil cytoplasmic antibody (ANCA) associated vasculitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Prematurely Ended) DE (Prematurely Ended) NL (Prematurely Ended) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2010-021715-17 | Sponsor Protocol Number: 1220.7 | Start Date*: 2011-07-12 | |||||||||||
| Sponsor Name:Boehringer Ingelheim Limited | |||||||||||||
| Full Title: A phase III, randomised, double-blind and placebo controlled study of once daily BI 201335, 240 mg for 12 or 24 weeks in combination with pegylated interferon-α and ribavirin in patients with genot... | |||||||||||||
| Medical condition: Chronic hepatitis C infection genotype 1 | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (Completed) PT (Completed) BE (Completed) DE (Completed) AT (Completed) ES (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2020-003084-26 | Sponsor Protocol Number: CHK0101 | Start Date*: 2021-04-08 |
| Sponsor Name:Chinook Therapeutics U.S., Inc. | ||
| Full Title: A Phase 3, Randomized, Double-blind, Placebo-controlled Study of Atrasentan in Patients with IgA Nephropathy at Risk of Progressive Loss of Renal Function (The ALIGN Study) | ||
| Medical condition: Immunoglobulin A Nephropathy (IgAN) | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Trial now transitioned) PL (Trial now transitioned) FR (Trial now transitioned) IT (Trial now transitioned) CZ (Completed) IE (Completed) PT (Trial now transitioned) | ||
| Trial results: (No results available) | ||
| EudraCT Number: 2014-000880-42 | Sponsor Protocol Number: HM14/10152 | Start Date*: 2014-11-12 | |||||||||||
| Sponsor Name:University of Leeds | |||||||||||||
| Full Title: GALACTIC: GA-101 (obinutuzumab) monocLonal Antibody as Consolidation Therapy In CLL | |||||||||||||
| Medical condition: Chronic Lymphocytic Leukaemia (CLL). | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: GB (GB - no longer in EU/EEA) | |||||||||||||
| Trial results: (No results available) | |||||||||||||
| EudraCT Number: 2018-000100-41 | Sponsor Protocol Number: PN018 | Start Date*: 2018-11-21 | ||||||||||||||||
| Sponsor Name:Abide Therapeutics, Inc. | ||||||||||||||||||
| Full Title: A Randomized, Placebo-Controlled Study of ABX-1431 in Adult Patients with Tourette Syndrome or Chronic Motor Tic Disorder | ||||||||||||||||||
| Medical condition: Tourette syndrome or chronic motor tic disorder | ||||||||||||||||||
|
||||||||||||||||||
| Population Age: Adults | Gender: Male, Female | |||||||||||||||||
| Trial protocol: ES (Completed) | ||||||||||||||||||
| Trial results: View results | ||||||||||||||||||
| EudraCT Number: 2007-006287-29 | Sponsor Protocol Number: AC2110664 | Start Date*: 2008-06-20 |
| Sponsor Name:GlaxoSmithKline Research & Development Ltd | ||
| Full Title: Dose ranging study for GSK233705B delivered once daily in subjects with COPD. | ||
| Medical condition: Chronic Obstructive Pulmonary (COPD) disease | ||
| Disease: | ||
| Population Age: Adults, Elderly | Gender: Male, Female | |
| Trial protocol: DE (Completed) GB (Completed) HU (Completed) NL (Completed) BG (Completed) | ||
| Trial results: View results | ||
| EudraCT Number: 2011-003409-36 | Sponsor Protocol Number: GA27927 | Start Date*: 2011-11-14 | |||||||||||
| Sponsor Name:Genentech, Inc. | |||||||||||||
| Full Title: A Phase II Open-Label Extension Study to Evaluate the Long-Term Safety of rhuMAb Beta7 in Patients with Moderate to Severe Ulcerative Colitis | |||||||||||||
| Medical condition: Ulcerative colitis | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: BE (Completed) DE (Completed) CZ (Completed) ES (Completed) GB (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
| EudraCT Number: 2009-012179-82 | Sponsor Protocol Number: B0401005 | Start Date*: 2010-01-05 | |||||||||||
| Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017 | |||||||||||||
| Full Title: A PHASE 2 MULTICENTER, DOUBLE-BLIND, PLACEBO CONTROLLED, PARALLEL GROUP STUDY OF PF-04447943 IN SUBJECTS WITH MILD TO MODERATE ALZHEIMER’S DISEASE | |||||||||||||
| Medical condition: Alzheimer’s Disease | |||||||||||||
|
|||||||||||||
| Population Age: Adults, Elderly | Gender: Male, Female | ||||||||||||
| Trial protocol: CZ (Completed) | |||||||||||||
| Trial results: View results | |||||||||||||
Subscribe to this Search
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
To subscribe to the RSS feed for this search click here
.
This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.
| Download Options: | |
|---|---|
| Number of Trials to download: | |
| Download Content: | |
| Download Format: | |
| Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial. | |
Query did not match any studies.